MTOR and renal cell carcinoma: Search terms were combinations of “renal cell carcinoma,” “localized,” “neoadjuvant,” “adjuvant,” “perioperative,” “systemic therapy,” “immune checkpoint inhibitor,” “VEGFR TKI,” “IO-TKI,” “mTOR inhibitor,” and “biomarker.” No language or date restrictions were applied; non-human studies were excluded. Reference lists of included articles and relevant reviews were also screened to identify additional studies.